Borrelia burgdorferi
Clinical TherapeuticsPatients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study EnrollmentErythema migrans is the most common clinical manifestation of Lyme disease, with concomitant subjective symptoms occurring in ∼65% of cases in the United States. We evaluated the impact of having been started on antibiotic treatment before study enrollment on 12 particular symptoms for 38 subjects with erythema migrans versus 52 untreated subjects. There were no significant differences in the frequency of having at least one symptom or...
Clinical TherapeuticsMolecular Testing of Serial Blood Specimens from Patients with Early Lyme Disease during Treatment Reveals Changing Coinfection with Mixtures of Borrelia burgdorferi GenotypesBorrelia burgdorferi is the etiological agent of Lyme disease. In the current study, we used direct-detection PCR and electrospray ionization mass spectrometry to monitor and genotype B. burgdorferi isolates from serially collected whole-blood specimens from patients clinically diagnosed with early...
Experimental TherapeuticsIdentifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferiBorrelia burgdorferi is the causative agent of Lyme borreliosis. Antibiotic therapy of early acute infection is effective for most patients, but 10 to 20% go on to develop posttreatment Lyme disease syndrome (PTLDS).
- Experimental TherapeuticsIneffectiveness of Tigecycline against Persistent Borrelia burgdorferi
- Experimental TherapeuticsPersistence of Borrelia burgdorferi following Antibiotic Treatment in Mice
- Mechanisms of ResistanceMutations Conferring Aminoglycoside and Spectinomycin Resistance in Borrelia burgdorferi
- Mechanisms of ResistanceparC Mutations in Fluoroquinolone-Resistant Borrelia burgdorferi